For older AML populations ineligible for intensive chemotherapy and allogeneic stem cell transplantation, combining the BH3 mimetic venetoclax (VEN) with hypomethylating agents has emerged as first-line therapy. Despite early responses, resistance to VEN, marked by...
Among the spectrum of mutations driving malignancy, mutation in the TP53 gene is perhaps the most important event leading to therapy resistance. Only ~25% of patients with TP53-mutated acute myeloid leukemia (AML) respond to standard induction therapy, with dismal...
Imetelstat is a first-in-class telomerase inhibitor with recent FDA approval for the treatment of myelodysplastic syndromes (Platzbecker et al. Lancet 2024). We have previously shown that imetelstat is effective in randomized, preclinical trials in Acute Myeloid...
Venetoclax (VEN) combined with low-dose cytarabine (LDAC) is highly effective in acute myeloid leukemia (AML) with either measurable residual disease (MRD) or oligoblastic (5-15% blasts) relapse (VALDAC study) (Tiong et al, JCO 2024). We have previously shown that...
Acute myeloid leukemia (AML) is a highly aggressive and deadly blood cancer with less than 30% five-year survival. AML develops when hematopoietic stem cells (HSC) or hematopoietic stem and progenitor cells (HSPC) acquire key mutations resulting in leukemic stem cell...
Despite extensive efforts aimed toward the development of improved molecular therapies targeting acute myeloid leukemia (AML), clinical outcomes remain poor. Notably, targeting BCL2 with venetoclax (Ven) in combination with azacitidine (Aza) has clinically delivered...
Recent Comments